Search

Displaying results 4411 - 4420 of 5504 in total
  1. Drug

    Pradofloxacin

    go.drugbank.com/drugs/DB11453
    ExperimentalVet approved

    It was approved by the European Commission in April 2011 for bacterial infections in dogs and cats.

  2. Drug

    Talampanel

    go.drugbank.com/drugs/DB04982
    Investigational

    It is a type of AMPA receptor antagonist.

  3. Drug

    CPG 10101

    go.drugbank.com/drugs/DB05530
    Investigational

    It is a toll-like receptor 9 (TLR9) agonist with antiviral and immunomodulatory properties that could potentially influence chronic infection with HCV.

  4. Drug

    Ostabolin-C

    go.drugbank.com/drugs/DB05536
    Investigational

    Ostabolin C was under investigation in clinical trial NCT00787358 (A Proof-of-Concept Study Investigating the Safety and Efficacy of ZT-031 on Hip Fracture Healing in Men and Postmenopausal Women (SHIFT

  5. Drug

    AC-100

    go.drugbank.com/drugs/DB05671
    Investigational

    It is being developed by Acologix, Inc.

  6. Drug

    Rexlemestrocel-L

    go.drugbank.com/drugs/DB17606
    Investigational

    It is being investigated in various cardiac conditions, such as chronic heart failure and acute myocardial infarction.

  7. Drug

    DCVAC/OvCa

    go.drugbank.com/drugs/DB18571
    Investigational

    It is under investigation for the treatment of ovarian cancer.

    Synonyms: Autologous dendritic cells pulsed with killed ovarian cancer cells and matured by TLR3 ligand ex vivo
  8. Drug

    Boldenone

    go.drugbank.com/drugs/DB01541
    ExperimentalIllicitVet approved

    It is not indicated for use in humans in the US and is only available through veterinary clinics.

  9. Drug

    Equilin

    go.drugbank.com/drugs/DB02187
    Experimental

    It has a total of four double bonds in the A- and B-ring. High concentration of equilin is found in the urine of pregnant mares.

  10. Drug

    NP-50301

    go.drugbank.com/drugs/DB05662
    Experimental

    It is being developed by Nascent Pharmaceuticals. It is estimated that about 30% of postmenopausal women suffer symptoms of DES, which accounts for over 12 million women in the U.S.